



PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q61459

Daikichi FUKUSHIMA, et al.

Appln. No.: 09/700,397

Group Art Unit: 1634

Confirmation No.: 3598

Examiner: A. Chakrabarti

Filed: November 14, 2000

For: NOVEL POLYPEPTIDES, cDNA ENCODING THE SAME, AND USE OF THEM

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed (without a Statement Under 37 C.F.R. § 1.97(e)) after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore a check for the fee of \$180.00 under 37 C.F.R. § 1.17(p) is attached. The

USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the

INFORMATION DISCLOSURE STATEMENT


U.S. Appln. No.: 09/700,397

Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said

Deposit Account. A duplicate copy of this paper is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: February 7, 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

1

of

1

Application Number	09/700,397
Confirmation Number	3598
Filing Date	November 14, 2000
First Named Inventor	Daikichi FUKUSHIMA
Art Unit	1634
Examiner Name	A. Chakrabarti
Attorney Docket Number	Q61459

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			RECEIVED
		US			
		US			FEB 13 2003
		US			
		US			TECH CENTER 1600/290
		US			
		US			
		US			

[illegible]

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		H. Huang, et al. Carboxypeptidase A3 (CPA3): A novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancel cells. <i>Cancer Res.</i> 59:2981-2988 (1999).	

Date Considered

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.